Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 9.7% – Here’s What Happened

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) shares rose 9.7% during mid-day trading on Tuesday. The stock traded as high as $14.43 and last traded at $14.37. Approximately 1,495,421 shares changed hands during mid-day trading, a decline of 13% from the average session volume of 1,725,033 shares. The stock had previously closed at $13.10.

More Syndax Pharmaceuticals News

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Syndax reported that 19 Revuforj (revumenib) and Niktimvo abstracts were accepted for ASH 2026, including seven oral presentations. The data cover multiple leukemia settings and could provide pipeline catalysts. ASH abstract announcement
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $36 target, with small increases to its Q4 2026 and 2029–30 earnings estimates. The firm’s long-range forecasts anticipate a return to profitability, though that remains a forward-looking projection. HC Wainwright estimates
• Neutral Sentiment: Syndax named Aaron A. Ondrey as CFO and scheduled an investor event for December 14. These announcements provide company updates but do not, by themselves, signal a change in business performance. CFO transition Investor event announcement
• Negative Sentiment: HC Wainwright lowered its FY2027 EPS estimate to a loss of $1.36 per share from a loss of $0.79, and changed its FY2028 estimate from a profit to a loss. Separately, Syndax’s latest reported quarterly loss per share missed estimates, despite revenue beating expectations and rising year over year. Pomerantz also said it is investigating investor claims, adding a potential legal overhang; the announcement provided no details about the claims. Pomerantz investigation announcement

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Weiss Ratings upgraded shares of Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Mizuho set a $43.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday. HC Wainwright lowered their price objective on shares of Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday. JPMorgan Chase & Co. dropped their price objective on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $41.60.

Syndax Pharmaceuticals Stock Performance

The stock has a fifty day moving average of $16.54 and a 200-day moving average of $20.07. The firm has a market capitalization of $830.28 million, a P/E ratio of -3.97 and a beta of 0.48. The company has a quick ratio of 6.44, a current ratio of 4.69 and a debt-to-equity ratio of 38.95.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.05). The firm had revenue of $83.30 million during the quarter, compared to the consensus estimate of $81.38 million. Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 804.38%. The company’s revenue was up 81.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.70) EPS. On average, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.03 EPS for the current year.

Insider Activity

In related news, Director Dennis Podlesak sold 8,000 shares of Syndax Pharmaceuticals stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $14.21, for a total value of $113,680.00. Following the sale, the director owned 239,763 shares of the company’s stock, valued at approximately $3,407,032.23. The trade was a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SNDX. CenterBook Partners LP acquired a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at approximately $5,137,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Syndax Pharmaceuticals in the third quarter valued at $86,000. China Universal Asset Management Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 15.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,293 shares of the company’s stock worth $297,000 after buying an additional 2,191 shares during the last quarter. Sterling Capital Management LLC increased its holdings in Syndax Pharmaceuticals by 846.6% during the third quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock worth $56,000 after buying an additional 2,650 shares during the last quarter. Finally, Inspire Investing LLC increased its holdings in Syndax Pharmaceuticals by 10.2% during the third quarter. Inspire Investing LLC now owns 34,122 shares of the company’s stock worth $641,000 after buying an additional 3,157 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.